Solid Biosciences Inc SLDB
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-01-26 |
| Shares Out. | 98,450,000 |
| Website | solidbio.com/ ↗ |
| Phone | 16173374680 |
| Employees | 121 |
| Net Income | -$56.7M |
| Free Cash Flow | -$172.9M |
| Total Assets | $422.9M |
| Total Liabilities | $48.8M |
| Equity | $374.1M |
About Solid Biosciences Inc
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Solid Biosciences Inc is a publicly traded company under the ticker symbol SLDB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)